Clascoterone for Hair Loss: 2026 Trial Updates and Launch Plans

Clascoterone 5% solution is an investigational topical treatment for male pattern hair loss. Phase III results have been announced, but a filing plan is not an approval or launch date. On July 23, 2026, Cosmo outlined US filing plans for the first quarter of 2027 and European plans for the second quarter.^schedule

This article explains public updates checked through October 10, 2026, for the candidate also known as Breezula. It interprets company announcements; it is not a treatment recommendation based on a review of the complete trial publication.

What is clascoterone being developed to do?

The 5% solution targets androgen receptor signaling in the scalp. It differs from Winlevi, the 1% acne cream containing the same ingredient, in formulation, concentration, and intended use.^trial Approval of an acne product should not be read as approval of a hair-loss treatment.

A recent PubMed review also concerns the 1% acne treatment. Finding the same ingredient in a paper does not establish evidence for treating scalp hair loss.^acne

What did the 2026 Phase III update show?

According to Cosmo's April 15 announcement, SCALP 1 and SCALP 2 enrolled 1,465 men. The extension compared continuing treatment with switching to vehicle in initial six-month responders. Cosmo reported continued hair-count improvement and safety comparable with vehicle.^trial

That design matters: the extension addresses treatment continuation in selected responders. It does not provide an all-participant prediction of one-year results.

To judge the findings more fully, readers need:

• Absolute hair-count changes within the measured area.
• The proportion experiencing a visible improvement.
• Adverse-event frequencies and reasons for withdrawal.
• Any direct comparisons with established treatments.

The announcement is useful, but comes from the developer. Cosmo said it plans to publish the full Phase III dataset.^trial

Does an impressive percentage mean it beats existing drugs?

The material reviewed here does not establish that conclusion. Comparing a treatment with vehicle, comparing continuation with withdrawal, and comparing two active drugs answer different questions. A relative improvement should not be presented as the percentage increase in someone's total scalp coverage.

Likewise, a new mechanism does not by itself establish greater benefit or freedom from adverse effects. A decision to change treatment needs prescribing information, relevant evidence, and an individual clinical assessment rather than a headline number.

Is a launch date or price confirmed?

The July update describes 2027 regulatory application targets.^schedule Review and commercial preparation still separate an application from availability. It would be misleading to turn that plan into a guaranteed 2027 launch. The announcement also does not establish Korean approval timing or pricing.

News you encounter	Question to ask
Phase III results	Are detailed results and the full paper available?
Planned filing	In which jurisdiction, and when?
Approval announcement	Does it concern the 5% hair-loss solution?
An offer to buy locally	Is there verifiable local authorization and distribution?

Should you delay treatment while waiting?

Do not stop prescribed treatment or postpone evaluation solely because of a projected launch. AAD describes diagnosis as involving medical history and scalp assessment, with tests when appropriate.^diagnosis

Sudden, patchy, scarring, painful, or rapidly worsening loss warrants assessment by a dermatologist. Drug-development news describes a possible future option; it cannot identify the cause of your current hair loss.